- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Viveve Announces Expansion of CMRF Technology Platform into Stress Urinary Incontinence Market
Viveve Medical (NASDAQ: VIVE) a medical technology company focused on women’s intimate health, today announced the expansion of its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform into the stress urinary incontinence (SUI) market, the results from a recently completed 12-month pilot study and plans for two clinical registration studies to further assess the safety and efficacy of …
Viveve Medical (NASDAQ: VIVE) a medical technology company focused on women’s intimate health, today announced the expansion of its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform into the stress urinary incontinence (SUI) market, the results from a recently completed 12-month pilot study and plans for two clinical registration studies to further assess the safety and efficacy of the Viveve System in the treatment of mild-to-moderate SUI.
As quoted in the press release:
“Our practice has treated women with vaginal laxity using Viveve’s CMRF technology for more than five years. For SUI, the combined cooling and deep tissue capability of CMRF effectively targets the connective tissue that plays a critical role in the structural integrity of the vagina and the urinary system. In the pilot study, we found that SUI symptoms were significantly improved, providing strong support for the planned clinical registration studies and the potential to represent a major advance in the non-invasive treatment of SUI,” said Dr. Allan.
Click here to read the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.